U.S. Metals and Mining Stock News

Earlier this year, Calumet reported quarterly results showing a 9.4% year-on-year increase in revenue but falling short of analysts’ revenue and EBITDA expectations. The combination of revenue growth and an earnings miss highlighted investors’ focus on Calumet’s longer-term transformation story rather than short-term forecast deviations. We’ll now examine how this mix of year-on-year revenue growth and weaker-than-expected EBITDA shapes Calumet’s broader investment narrative. The best AI...

Why ANI Pharmaceuticals Is On Investors’ Radar Today ANI Pharmaceuticals (ANIP) is drawing attention after recent share price moves, with the stock up about 5% over the past month but showing a roughly 8% decline over the past 3 months. See our latest analysis for ANI Pharmaceuticals. Looking past the recent 5.1% 1 month share price return, ANI Pharmaceuticals’ share price has softened over the last quarter while the 1 year total shareholder return of 12.8% and 5 year total shareholder return...

Wondering if TG Therapeutics at around US$34.30 is pricing in too much hope or not enough future potential? This article breaks down what that current tag may actually reflect. The stock has been volatile, with a 1% decline over the last 7 days, an 8.9% gain over 30 days, a 17.1% gain year to date, but a 10.5% decline over the past year and a 16.5% decline over 5 years, all against a 60.4% gain over 3 years. Recent news coverage around TG Therapeutics has focused on its position within the...

If you are wondering whether BJ's Wholesale Club Holdings is priced attractively or already reflects its strengths, it helps to start with how the current share price lines up against different valuation checks. The stock closed at US$92.24, with returns of a 1.5% decline over 7 days, a 4.4% decline over 30 days, a small 0.3% gain year to date, and a 22.1% decline over the last year, following a 19.0% return over 3 years and 112.9% over 5 years. Recent coverage has focused on BJ's position...

Leadership change puts BioCryst’s R&D focus in the spotlight BioCryst Pharmaceuticals (BCRX) recently named Sandeep M. Menon as Chief Research and Development Officer, putting fresh attention on how new leadership could shape the company’s rare disease pipeline and longer term growth plans. See our latest analysis for BioCryst Pharmaceuticals. The appointment of Dr. Menon comes at a time when BioCryst’s share price has a 90 day share price return of 42.9% and a 1 year total shareholder return...

CRA International (CRAI) is back in focus after recent share price swings. The stock has been roughly flat over the past year but has shown a negative move over the past 3 months. See our latest analysis for CRA International. Recent trading tells a mixed story, with a 4.1% 30 day share price return set against a 23.1% decline over 90 days, while the 5 year total shareholder return of 126.2% reflects much stronger long term performance. If CRA International’s recent swings have you thinking...

Spire (NYSE:SR) agreed to sell its natural gas storage assets in Wyoming and Oklahoma to I Squared Capital. The transaction shifts Spire's portfolio toward regulated natural gas utilities and supports funding for its recent Nashville acquisition. The move reflects a material change in business mix and risk profile that has not yet been widely discussed. Spire is primarily a regulated natural gas utility, and this agreement to sell Wyoming and Oklahoma storage assets tightens that focus. By...

Over the last 7 days, the United States market has experienced a significant decline of 29%, contributing to an overall drop of 82% over the past year, though earnings are forecast to grow by 16% annually. In such volatile conditions, identifying stocks that are undervalued relative to their intrinsic value can present opportunities for investors seeking potential long-term gains.

If you are wondering whether Gap's share price still offers value after a strong run, or if most of the opportunity is already priced in, this article breaks down what the current market price might be implying about the company. Gap's stock has seen a 40.3% return over the last year and 209.3% over the last 3 years, while the most recent 7 day return of a 1.1% decline sits against a 9.4% gain over the last 30 days and a 3.5% return year to date. Recent headlines around Gap have focused on...

Over the last 7 days, the United States market has experienced a significant drop of 29%, contributing to an overall decline of 82% over the past year. In light of these challenging conditions, identifying growth companies with substantial insider ownership can be particularly appealing as it often indicates confidence in future performance and alignment with shareholder interests.

Over the last 7 days, the United States market has experienced a significant downturn, dropping 29%, and is down 82% over the past year, though earnings are forecast to grow by 16% annually. In challenging market conditions like these, identifying stocks with strong financial fundamentals becomes crucial for investors seeking potential opportunities. Although "penny stocks" may seem like an outdated term, they continue to represent smaller or newer companies that can offer both affordability...

Earlier this month, Annexon, Inc. presented at the 25th Annual Needham Virtual Healthcare Conference, where CEO Douglas E. Love outlined the company’s upcoming clinical and regulatory milestones. A key takeaway was management’s description of 2026 as a “win year,” highlighting expected GBS regulatory filings, a Phase III geographic atrophy readout, and proof-of-concept data for ANX1502, all supported by a cash runway projected into the second half of 2027. We’ll now look at how this “win...

Over the last 7 days, the United States market has experienced a significant drop of 29%, and over the past year, it has declined by 82%, though earnings are expected to grow by 16% per annum in the coming years. In this challenging environment, identifying stocks with strong fundamentals and growth potential can be key to uncovering hidden gems that may offer promising opportunities.

MPLX (NYSE:MPLX) has secured a new multi year, multi billion dollar revolving credit agreement totaling $2.5 billion. The facility replaces prior credit lines and is designed to support future partnership activities and liquidity needs. Sponsor Marathon Petroleum has also renewed its own multi year revolving credit agreement with a broad banking group. MPLX enters this refinancing with units trading at $55.24 and a 1 year return of 18.2%. Over 3 years, the return is 104.8%, and over 5 years...

Lam Research (NasdaqGS:LRCX) is being approached as a core equipment supplier for Elon Musk's Terafab project, a multi company US semiconductor manufacturing initiative targeting 2029. Terafab involves companies such as Tesla, SpaceX, Intel, and xAI, with an ambition to build a large scale facility focused on advanced 2nm chip production. The project aims to bring more of the semiconductor production chain onshore in the US, potentially reshaping supplier relationships across the...

For readers wondering if Taysha Gene Therapies at around US$5.95 is still offering value or if most of the opportunity is already reflected in the price, this article walks through what the current valuation actually implies. The stock has shown sharp moves recently, with returns of 28.5% over 7 days, 30.2% over 30 days, 13.3% year to date and 379.8% over the last year. Over a 3 year period the return is around 7x, while the 5 year return shows a 74.3% decline. Recent attention has focused...

SL Green Realty (SLG) opened 2026 with Q1 funds from operations of US$64.6 million, or US$0.85 FFO per share, setting the tone for how its New York office portfolio is currently earning its keep. Over the past several quarters the company has seen quarterly revenue reported at US$251.2 million in Q4 2025 and US$241.0 million in Q1 2025, alongside EPS figures that ranged from a loss of US$1.49 per share in Q4 2025 to a small profit of US$0.13 per share in Q4 2024. Taken together, these numbers...

CoreCivic (NYSE:CXW) has amended its credit agreement to add a $100 million Incremental Term Loan. The company plans to use the proceeds to refinance outstanding revolver borrowings and for general corporate purposes. This financing step adjusts CoreCivic’s capital structure and affects its available liquidity profile. For investors watching CoreCivic at a current share price of $20.22, this credit agreement amendment is an important capital structure event. The stock shows mixed...

If you are wondering whether Akamai Technologies is fairly priced today, the key question is how its current share price compares with a grounded view of its long term cash generation. The stock closed at US$96.81, with an 11.7% decline over the last 7 days and an 8.5% decline over the last 30 days, while still showing a 13.8% return year to date and 31.8% over the last year. Recent headlines around Akamai often center on its role in content delivery, cloud security and edge computing, which...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Vertical Aerospace (NYSE:EVTL) has drawn fresh attention after completing a two-way piloted transition flight in its full-scale tiltrotor eVTOL. This is a key step that validates its electric air taxi concept under civil aviation oversight. See our latest analysis for Vertical Aerospace. The successful transition flight has arrived alongside sharp short term share price momentum, with a 1 day share price return of 25.56% and 7 day return of 45.22%. However, this sits against a weaker 90 day...

Clearway Energy is asking stockholders to approve a plan to consolidate its public share classes into a single share class. The company is seeking this approval at an upcoming stockholder meeting as part of an effort to simplify its equity structure. Proxy advisory firm ISS has recommended that investors vote "FOR" the proposed share class unification. For investors tracking NYSE:CWEN.A, the proposal comes as Clearway Energy trades at a share price of $39.98 and carries a value score of 3...

Wondering if Nabors Industries at around US$82.24 is priced for its risks or offering genuine value? This article focuses squarely on what the current share price could mean for you. The stock is roughly flat over the last week with a 0.8% decline, but is up 3.0% over 30 days and 48.4% year to date, while the 1 year return sits at 166.1% against weaker 3 year and 5 year returns of 28.3% and 1.3% declines. Recent trading interest reflects how investors are reassessing Nabors Industries after...

Morgan Stanley ( NYSE:MS ) just released its latest quarterly results and things are looking bullish. Morgan Stanley...